Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090185 | 0.84 | KDM4E (0.31) | SRD5A2LMNAMAPTKDM4EMEN1 | |
| SCHEMBL3706674 | 0.77 | KDM4E (0.32) | SRD5A2LMNAMAPTKDM4EMEN1 | |
| SCHEMBL8089735 | 0.75 | CYP1A2 (0.35) | MAPTKDM4EMEN1KMT2AUSP2 | |
| SCHEMBL20658012 | 0.63 | SMN1; SMN2 (0.36) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL8091709 | 0.63 | CYP1A2 (0.33) | — | |
| SCHEMBL4338458 | 0.62 | — | — | |
| SCHEMBL4594212 | 0.61 | PIK3CD (0.55) | MAPTL3MBTL1 | |
| SCHEMBL29471355 | 0.60 | NPSR1 (0.32) | MAPT | |
| SCHEMBL17596363 | 0.60 | HDAC3 (0.36) | LMNAMAPTMEN1KMT2AUSP2 | |
| SCHEMBL8086329 | 0.60 | KDM4E (0.35) | MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009013535-A1 | 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |